Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PYGM | P11217 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10380346 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBKMT2APYGM | |
| SCHEMBL24695865 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBKMT2APYGM | |
| Phosphoric Acid SCHEMBL3691397 | 0.95 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2POLBKMT2APYGM | |
| SCHEMBL21277516 | 0.90 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2POLBKMT2APYGM | |
| SCHEMBL23485 | 0.85 | LMNA (0.58) | ALDH1A1POLBLMNAALBTK1 | |
| SCHEMBL22992337 | 0.85 | LMNA (0.58) | ALDH1A1POLBLMNAALBTK1 | |
| SCHEMBL14596607 | 0.85 | LMNA (0.58) | ALDH1A1POLBLMNAALBTK1 | |
| SCHEMBL19657129 | 0.85 | LMNA (0.48) | ALDH1A1SMN1; SMN2POLBLMNAALB | |
| SCHEMBL762579 | 0.85 | LMNA (0.58) | ALDH1A1POLBLMNAALBTK1 | |
| SCHEMBL925743 | 0.85 | LMNA (0.58) | ALDH1A1POLBLMNAALBTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580609-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-119789852-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024050372-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116064869-A | Diagnosis of drug-resistant Mycobacterium tuberculosis using mass spectrometry | 贝克顿迪金森公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-101564571-B | Medical apparatus containing rapamycin analogue | 艾博特公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9394565-B2 | Allele-specific sequence variation analysis | AGENA BIOSCIENCE, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-8871687-B2 | Nucleic acid sequencing by single-base primer extension | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2014-10-28 | — | — | US | disclosed |
| CN-101637624-B | Medical devices containing rapamycin analogs | ABBOTT LABORATORIES (US) | 2014-10-15 | — | — | CN | disclosed |
| WO-2005033328-A2 | COMPOSITIONS AND PROCESSES FOR GENOTYPING SINGLE NUCLEOTIDE POLYMORPHISMS | PERKINELMER LAS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005024068-A2 | ALLELE-SPECIFIC SEQUENCE VARIATION ANALYSIS | SEQUENOM, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050009053-A1 | Fragmentation-based methods and systems for de novo sequencing | SEQUENOM, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004097369-A2 | FRAGMENTATION-BASED METHODS AND SYSTEMS FOR DE NOVO SEQUENCING | SEQUENOM, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004050839-A2 | FRAGMENTATION-BASED METHODS AND SYSTEMS FOR SEQUENCE VARIATION DETECTION AND DISCOVERY | SEQUENOM, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040077004-A1 | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and highly multiplexed nucleic acid sequencing | TRUSTEES OF BOSTON UNIVERSITY, THE | 2004-04-22 | — | — | US | disclosed |
| EP-1373561-A2 | USE OF NUCLEOTIDE ANALOGS IN THE ANALYSIS OF OLIGONUCLEOTIDE MIXTURES AND IN HIGHLY MULTIPLEXED NUCLEIC ACID SEQUENCING | The Trustees of Boston University (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6660229-B2 | Synthesizing extension products of the target nucleic acid in the presence of chain terminating nucleotides and mass-matched nucleotides; determining the mass of each extension product; and calculating a mass shift | THE TRUSTEES OF BOSTON UNIVERSITY | 2003-12-09 | — | — | US | disclosed |
| US-20020045178-A1 | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing | THE TRUSTEES OF BOSTON UNIVERSITY | 2002-04-18 | — | — | US | disclosed |
| WO-2001096607-A2 | USE OF NUCLEOTIDE ANALOGS IN THE ANALYSIS OF OLIGONUCLEOTIDE MIXTURES AND IN HIGHLY MULTIPLEXED NUCLEIC ACID SEQUENCING | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | ALDH1A1 833/4885SMN1; SMN2 3957/4885POLB 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.